Racecadotril
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Racecadotril: From Acute Diarrhea to Polyclonal Hyperviscosity Syndrome
One-Sentence Summary
Racecadotril is an enkephalinase (NEP/CD10) inhibitor established as an antidiarrheal agent for acute diarrhea, reducing intestinal hypersecretion without affecting gut motility. The TxGNN model predicts potential efficacy for Polyclonal Hyperviscosity Syndrome, but this direction is currently supported by 0 clinical trials and 0 publications, and the evidence pack’s own mechanistic assessment flags the link as a likely knowledge-graph topological artifact rather than a substantiated pharmacological relationship.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acute diarrhea (antidiarrheal, antisecretory) — inferred from background context in the prediction rationale, not from an India regulatory filing, since the drug is not marketed in India |
| Predicted New Indication | Polyclonal Hyperviscosity Syndrome |
| TxGNN Prediction Score | 97.72% |
| Evidence Level | L5 |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Racecadotril is flagged as a data gap (DG002) and could not be independently verified. However, the evidence pack’s own prediction rationale identifies Racecadotril as an inhibitor of neutral endopeptidase (NEP/CD10/enkephalinase), an enzyme also expressed on lymphoid and plasma cell lineages and involved in the metabolism of various peptides.
The proposed link to Polyclonal Hyperviscosity Syndrome rests on this shared NEP/CD10 node rather than on any demonstrated pharmacodynamic effect on immunoglobulin production or blood viscosity. The evidence pack explicitly characterizes this as a speculative association: the TxGNN high score likely reflects topological proximity between NEP-related nodes and hematologic disease nodes in the knowledge graph, not a validated mechanistic pathway. No preclinical, clinical, or case-based evidence currently connects enkephalinase inhibition to plasma viscosity or immunoglobulin regulation.
Given this, the mechanistic rationale should be read as a hypothesis-generating signal only, not as pharmacological support strong enough to justify clinical action without further validation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Racecadotril currently has no registered products in India (market status: Not marketed, 0 registrations), so no authorization details are available.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA/India-equivalent label warnings and contraindications are a Blocking data gap — DG001 — preventing a formal S1 safety pre-assessment.)
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has no clinical trial or literature support (L5, model prediction only), and the evidence pack’s own mechanistic review characterizes the drug-disease link as a likely graph-embedding artifact rather than a plausible pharmacological relationship. Combined with a blocking safety data gap and no India market presence, there is insufficient basis to advance.
To proceed, the following is needed:
- TFDA/India label warnings and contraindications (resolves DG001, required before any S1 safety pre-assessment)
- Confirmed mechanism-of-action data from DrugBank or primary literature (resolves DG002)
- Preclinical or mechanistic studies directly testing NEP/CD10 inhibition in the context of immunoglobulin production or plasma viscosity
- Any case reports, observational data, or pharmacovigilance signals linking Racecadotril to hematologic/viscosity-related outcomes
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.